Literature DB >> 22360717

Chronic myeloid leukemia and risk of second malignancy in two eras of treatment.

Brady L Stein1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360717     DOI: 10.3109/10428194.2012.668684

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  6 in total

Review 1.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

Review 2.  Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature.

Authors:  Nancy Kassem; Omar M Ismail; Halima Elomri; Mohamad A Yassin
Journal:  Am J Case Rep       Date:  2017-07-14

3.  A study of deregulated MMR pathways and anticancer potential of curcuma derivatives using computational approach.

Authors:  Priyanjali Bhattacharya; Trupti N Patel
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

Review 4.  Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature.

Authors:  Yasunobu Sekiguchi; Asami Shimada; Moe Matsuzawa; Hidenori Imai; Mutsumi Wakabayashi; Keiji Sugimoto; Noriko Nakamura; Tomohiro Sawada; Junichi Arita; Norio Komatsu; Masaaki Noguchi
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

5.  An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States.

Authors:  Vivek Kumar; Mohit Garg; Neha Chaudhary; Abhinav Binod Chandra
Journal:  PeerJ       Date:  2018-02-12       Impact factor: 2.984

6.  Clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia.

Authors:  Chunshui Liu; Cong Wang; Zhonghua Du; Hongwei Xue; Zhihe Liu
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.